Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary neuropathy with liability to pressure palsies (HNPP) is an inherited peripheral nerve disorder characterized by recurrent mononeuropathy usually triggered by minor physical activities.
Features include always present findings: Hyporeflexia, Hypoesthesia, Hand muscle weakness, and Decreased motor nerve conduction velocity and others. 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 3 | Hyporeflexia, Hand paresthesia, Peripheral neuropathy |
Muscles | 2 | Hand muscle weakness, Muscle weakness |
Arms and legs | 2 | Hand muscle weakness, Hand paresthesia |
Hereditary neuropathy with liability to pressure palsies (HNPP) is characterized by recurrent acute sensory and motor neuropathy in a single or multiple nerves. The most common initial manifestation is the acute onset of a non-painful focal sensory and motor neuropathy in a single nerve (mononeuropathy) . Some individuals experience transient sensory phenomena without weakness. A history of actual physical minor compression of the nerve may or may not be present. The first attack generally occurs in the second or third decade (age range: 2-70 years; mean 37 years) but could be at any age. With the widespread availability of molecular genetic testing, reports of early onset have become increasingly common .
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
PMP22 function has not been fully characterized.
Hereditary neuropathy with liability to pressure palsies is caused by mutations in the PMP22 gene on chromosome 17.
More than 26 single PMP22 nucleotide variants have been reported to cause HNPP. It is not clear if there are genotype-phenotype correlations with these variants since each is limited to a few families . Of note, six families with the PMP22 frameshift variant have a typical HNPP phenotype and are also more likely to have an associated clinically evident motor/sensory neuropathy mimicking Charcot-Marie-Tooth neuropathy type 1 (CMT1; see CMT Overview) . A similar phenotype has been described in individuals with other single-nucleotide variants in PMP22 [, , , , ].
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
Penetrance is 100% but expressivity is highly variable even within the same family. For an unknown reason men typically have more severe clinical nerve palsies and electrophysiologic studies.
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
Hereditary neuropathy with liability to pressure palsies (HNPP) should be suspected in individuals with the following clinical findings, electrophysiologic studies, imaging studies, and family history.
Typical clinical findings
Recurrent acute focal sensory and motor neuropathies mainly at entrapment sites
Painless nerve palsy after minor trauma or compression
Evidence on physical examination of previous nerve palsy such as focal weakness, atrophy, or sensory loss
Complete spontaneous recovery from neuropathies (in 50% of occurrences) within weeks
Mild-to-moderate pes cavus foot deformity (in 4%-40% of individuals)
Electrophysiologic studies
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
The signs and symptoms of compression neuropathy in hereditary neuropathy with liability to pressure palsies (HNPP) are the same as those of the acquired type. Thus, HNPP is part of the broad differential diagnosis of both compression neuropathies and general peripheral neuropathies, including the hereditary neuropathies and Charcot-Marie-Tooth (CMT) syndrome (see CMT Overview).
Compression neuropathies. Pressure palsies are most commonly the result of environmentally acquired physical compression of peripheral nerves. The most common are carpal tunnel syndrome with compression of the median nerve at the wrist,* peroneal pressure palsy with compression of the superficial peroneal nerve at the fibular head, and ulnar nerve compression at the elbow.
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
Genetic testing for PMP22 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hereditary neuropathy with liability to pressure palsies has been reported in the published literature.
No approved treatments are currently available for hereditary neuropathy with liability to pressure palsies. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 2.
Recommended Evaluations Following Initial Diagnosis in Individuals with HNPP
System/Concern | Evaluation | Comment
| Neurologic eval | To evaluate for pain determine:
Extent of weakness atrophy, pes cavus, gait stability, sensory loss
If there are assoc manifestations (e.g., focal atrophy or sensory loss in less common sites of entrapment)
If affected person /or a family member has had episodes of acute transient nerve palsy
| Orthopedics/ physical medicine rehab/ PT/OT evaluation | To incl assessment of:
Gross motor fine motor skills need for PT (to improve gross motor skills) /or OT (to improve fine motor skills)
Feet for evidence of pes cavus need for AFOs, specialized shoes
Mobility, ADL, need for adaptive devices
Need for handicapped parking
Genetic
counseling | By genetics professionals1 | To inform affected persons families re nature, MOI, implications of HNPP to facilitate medical personal decision making
Family support
resources | Assess need for:
Community resources (e.g., Parent to Parent);
Social work involvement for parental support.
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
Activities that are risk factors for pressure palsies include the following :
Prolonged sitting with legs crossed
Prolonged leaning on elbows
Occupations requiring repetitive movements of the wrist
Rapid weight loss
Wearing a heavy backpack on shoulders
Particular care must be taken in positioning during surgery (particularly knee surgery) to avoid nerve compression . Vincristine, commonly used in the chemotherapy of lymphoma, has been reported to exacerbate HNPP, as other potential neurotoxic chemotherapy or agents . Medications that are toxic or potentially toxic to persons with CMT comprise a spectrum of risk ranging from definite high risk to negligible risk. See the Charcot-Marie-Tooth Association website (pdf) for an up-to-date list.
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
1 trial found
Table 3.
Recommended Surveillance for Individuals with HNPP
System/Concern | Evaluation | Frequency
| Screening neurologic exam focused on muscle atrophy, strength, sensory loss | Annually
Eval for neuropathic pain
| PT (gross motor skills) ADL
OT (fine motor skills) ADL
| For pressure sores or poorly fitting footwear | Annually by physician; at more frequent intervals by affected person
ADL = activities of daily living; OT = occupational therapy; PT = physical therapy
Source: GeneReviews — "Hereditary Neuropathy with Liability to Pressure Palsies"
Phenotype severity distribution: 6 always present features.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
45 publications have been identified in PubMed for hereditary neuropathy with liability to pressure palsies. Research spans Case Report / Case Series (39%), Basic Science / Preclinical (25%), and Review / Meta-Analysis (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 17 | 39% |
Laboratory research | 11 | 25% |
Research summaries | 6 | 14% |
Disease patterns and progression | 6 | 14% |
Testing and diagnosis research | 3 | 7% |
New treatment approaches | 1 | 2% |
Nguyen TT (2026). [PMID: 42083668](https://pubmed.ncbi.nlm.nih.gov/42083668/). *Cureus*. [Case Report / Case Series]
Li YX (2026). [PMID: 41557084](https://pubmed.ncbi.nlm.nih.gov/41557084/). *Neurol Sci*. [Review / Meta-Analysis]
Ren Y (2026). [PMID: 42033181](https://pubmed.ncbi.nlm.nih.gov/42033181/). *Eur J Neurol*. [Basic Science / Preclinical]
AlHashem A (2026). [PMID: 41474134](https://pubmed.ncbi.nlm.nih.gov/41474134/). *Am J Med Genet A*. [Epidemiology / Natural History]
Raasveld FV (2026). [PMID: 42165586](https://pubmed.ncbi.nlm.nih.gov/42165586/). *Pain Manag*. [Review / Meta-Analysis]
Moss KR (2026). [PMID: 41400104](https://pubmed.ncbi.nlm.nih.gov/41400104/). *Glia*. [Basic Science / Preclinical]
Chausova P (2026). [PMID: 42074212](https://pubmed.ncbi.nlm.nih.gov/42074212/). *Int J Mol Sci*. [Gene Therapy / Novel Therapeutics]
Oberoi V (2026). [PMID: 41795901](https://pubmed.ncbi.nlm.nih.gov/41795901/). *Journal of the peripheral nervous system : JPNS*. [Basic Science / Preclinical]
Pomarino D (2026). [PMID: 41551139](https://pubmed.ncbi.nlm.nih.gov/41551139/). *Global medical genetics*. [Epidemiology / Natural History]
Capece G (2026). [PMID: 41841518](https://pubmed.ncbi.nlm.nih.gov/41841518/). *Eur J Neurol*. [Case Report / Case Series]
Data assembled from 9 of 12 sources · Last updated Sep 20, 2026, 1:42 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center